146 related articles for article (PubMed ID: 33492715)
1. Hepatocellular carcinoma and the risk of de novo malignancies after liver transplantation - a multicenter cohort study.
Shalaby S; Taborelli M; Zanetto A; Ferrarese A; D'Arcangelo F; Gambato M; Senzolo M; Russo FP; Germani G; Boccagni P; Ettorre GM; Baccarani U; Lauro A; Galatioto L; Rendina M; Petrara R; De Rossi A; Nudo F; Toti L; Fantola G; Vennarecci G; Risaliti A; Pinna AD; Gruttadauria S; Di Leo A; Rossi M; Tisone G; Zamboni F; Cillo U; Piselli P; Serraino D; Burra P;
Transpl Int; 2021 Apr; 34(4):743-753. PubMed ID: 33492715
[TBL] [Abstract][Full Text] [Related]
2. Time-varying Comparison of All-cause Mortality After Liver Transplantation Between Recipients With and Without Hepatocellular Carcinoma: A Population-based Cohort Study Using the United Kingdom Liver Transplant Registry.
Sehjal J; Sharples LD; Keogh RH; Walker K; Prachalias A; Heaton N; Ivanics T; van der Meulen J; Wallace D
Transplantation; 2022 Nov; 106(11):e464-e475. PubMed ID: 36017919
[TBL] [Abstract][Full Text] [Related]
3. Incidence and risk factors for hepatocellular carcinoma after solid organ transplantation.
Hoffmann CJ; Subramanian AK; Cameron AM; Engels EA
Transplantation; 2008 Sep; 86(6):784-90. PubMed ID: 18813102
[TBL] [Abstract][Full Text] [Related]
4. Worse Long-term Patient Survival and Higher Cancer Rates in Liver Transplant Recipients With a History of Smoking.
Mangus RS; Fridell JA; Kubal CA; Loeffler AL; Krause AA; Bell JA; Tiwari S; Tector J
Transplantation; 2015 Sep; 99(9):1862-8. PubMed ID: 26308417
[TBL] [Abstract][Full Text] [Related]
5. A novel prognostic nomogram accurately predicts hepatocellular carcinoma recurrence after liver transplantation: analysis of 865 consecutive liver transplant recipients.
Agopian VG; Harlander-Locke M; Zarrinpar A; Kaldas FM; Farmer DG; Yersiz H; Finn RS; Tong M; Hiatt JR; Busuttil RW
J Am Coll Surg; 2015 Apr; 220(4):416-27. PubMed ID: 25690672
[TBL] [Abstract][Full Text] [Related]
6. Pretransplant Hepatic Malignancy Increases Risk of De Novo Malignancy after Liver Transplantation.
Park GC; Hwang S; Ahn CS; Kim KH; Moon DB; Ha TY; Song GW; Jung DH; Yoon YI; Cho HD; Kwon JH; Chung YK; Kang SH; Choi JU; Jung IJ; Lee SG
J Korean Med Sci; 2020 Mar; 35(11):e69. PubMed ID: 32193900
[TBL] [Abstract][Full Text] [Related]
7. Clinical Significance of De Novo Malignancy After Liver Transplant: A Single-Center Study.
Kim S; Rovgaliyev B; Lee JM; Lee KW; Hong SK; Cho JH; Yoon KC; Yi NJ; Suh KS
Transplant Proc; 2021; 53(1):200-206. PubMed ID: 32409224
[TBL] [Abstract][Full Text] [Related]
8. Survival after the diagnosis of de novo malignancy in liver transplant recipients.
Taborelli M; Piselli P; Ettorre GM; Baccarani U; Burra P; Lauro A; Galatioto L; Rendina M; Shalaby S; Petrara R; Nudo F; Toti L; Fantola G; Cimaglia C; Agresta A; Vennarecci G; Pinna AD; Gruttadauria S; Risaliti A; Di Leo A; Rossi M; Tisone G; Zamboni F; Serraino D;
Int J Cancer; 2019 Jan; 144(2):232-239. PubMed ID: 30091809
[TBL] [Abstract][Full Text] [Related]
9. Immunosuppressive Treatment With mTOR Inhibitors for Malignancies After Liver Transplantation: Long-Term Survival Retrospective Analysis.
Tejedor-Tejada J; Alonso-Martín C; Almohalla-Álvarez C; Valenzuela EF; Muñoz RN; Delgado LS; Martín CM; Sánchez-Martín F; García-Pajares F; Sánchez-Antolín G
Transplant Proc; 2020 Jun; 52(5):1507-1510. PubMed ID: 32213292
[TBL] [Abstract][Full Text] [Related]
10. Cumulative exposure to tacrolimus and incidence of cancer after liver transplantation.
Rodríguez-Perálvarez M; Colmenero J; González A; Gastaca M; Curell A; Caballero-Marcos A; Sánchez-Martínez A; Di Maira T; Herrero JI; Almohalla C; Lorente S; Cuadrado-Lavín A; Pascual S; López-Garrido MÁ; González-Grande R; Gómez-Orellana A; Alejandre R; Zamora-Olaya J; Bernal-Bellido C;
Am J Transplant; 2022 Jun; 22(6):1671-1682. PubMed ID: 35286761
[TBL] [Abstract][Full Text] [Related]
11. Risk factors of de novo malignancies after liver transplantation: a French national study on 11004 adult patients.
Altieri M; Sérée O; Lobbedez T; Segol P; Abergel A; Blaizot X; Boillot O; Boudjema K; Coilly A; Conti F; Chazouillères O; Debette-Gratien M; Dharancy S; Durand F; Duvoux C; Francoz C; Gugenheim J; Hardwigsen J; Houssel-Debry P; Kamar N; Latournerie M; Lebray P; Leroy V; Neau-Cransac M; Pageaux GP; Radenne S; Salamé E; Saliba F; Samuel D; Vanlemmens C; Besch C; Launoy G; Dumortier J
Clin Res Hepatol Gastroenterol; 2021 Jul; 45(4):101514. PubMed ID: 33714907
[TBL] [Abstract][Full Text] [Related]
12. Pediatric liver transplantation for hepatocellular cancer and rare liver malignancies: US multicenter and single-center experience (1981-2015).
Vinayak R; Cruz RJ; Ranganathan S; Mohanka R; Mazariegos G; Soltys K; Bond G; Tadros S; Humar A; Marsh JW; Selby RR; Reyes J; Sun Q; Haberman K; Sindhi R
Liver Transpl; 2017 Dec; 23(12):1577-1588. PubMed ID: 28834194
[TBL] [Abstract][Full Text] [Related]
13. Liver transplantation recipients with nonalcoholic steatohepatitis have lower risk hepatocellular carcinoma.
Lewin SM; Mehta N; Kelley RK; Roberts JP; Yao FY; Brandman D
Liver Transpl; 2017 Aug; 23(8):1015-1022. PubMed ID: 28340509
[TBL] [Abstract][Full Text] [Related]
14. De novo hepatocellular carcinoma of liver allograft: a neglected issue.
Trevisani F; Garuti F; Cucchetti A; Lenzi B; Bernardi M
Cancer Lett; 2015 Feb; 357(1):47-54. PubMed ID: 25444925
[TBL] [Abstract][Full Text] [Related]
15. De Novo Malignancy After Adult-to-Adult Living Donor Liver Transplantation: A Single-Center Long-Term Experience.
Masuda Y; Mita A; Ohno Y; Kubota K; Notake T; Shimizu A; Soejima Y
Transplant Proc; 2023 May; 55(4):952-955. PubMed ID: 37088616
[TBL] [Abstract][Full Text] [Related]
16. Visceral adiposity increases risk for hepatocellular carcinoma in male patients with cirrhosis and recurrence after liver transplant.
Montano-Loza AJ; Mazurak VC; Ebadi M; Meza-Junco J; Sawyer MB; Baracos VE; Kneteman N
Hepatology; 2018 Mar; 67(3):914-923. PubMed ID: 29023899
[TBL] [Abstract][Full Text] [Related]
17. The Impact of Direct-acting Antivirals on Overall Mortality and Tumoral Recurrence in Patients With Hepatocellular Carcinoma Listed for Liver Transplantation: An International Multicenter Study.
Gorgen A; Galvin Z; Huang AC; Vinaixa C; O'Rourke JM; Francoz C; Hansen BE; Durand F; Elsharkawy AM; Shah T; Berenguer M; Rubin A; Calatayud D; Mehta N; Terrault NA; Lilly LB; Selzner N; Sapisochin G
Transplantation; 2020 Oct; 104(10):2087-2096. PubMed ID: 31978002
[TBL] [Abstract][Full Text] [Related]
18. Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S.
Wong RJ; Cheung R; Ahmed A
Hepatology; 2014 Jun; 59(6):2188-95. PubMed ID: 24375711
[TBL] [Abstract][Full Text] [Related]
19. Assessing Competing Risks for Death Following Liver Transplantation for Hepatocellular Carcinoma.
Sposito C; Cucchetti A; Mazzaferro V
Dig Dis Sci; 2019 Apr; 64(4):1001-1007. PubMed ID: 30852770
[TBL] [Abstract][Full Text] [Related]
20. Malignancy After Living Donor Liver Transplantation.
Kobayashi T; Miura K; Ishikawa H; Sakata J; Takizawa K; Hirose Y; Toge K; Saito S; Abe S; Kawachi Y; Ichikawa H; Shimada Y; Takahashi Y; Wakai T; Kinoshita Y
Transplant Proc; 2024 Apr; 56(3):660-666. PubMed ID: 38519268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
